title: Dorsalis pedis tendocutaneous delayed arterialized venous flap in hand reconstruction.
abstract: We report two patients whose acute soft-tissue and tendon defects in the hand were treated with a dorsalis pedis tendocutaneous delayed arterialized venous flap between 1994 and 1997. The surviving surface area was 100 percent in both patients. The flap sizes were 10 x 10 cm and 6 x 6 cm. At 2 weeks postoperatively, active flexion and passive extension commenced, and progressive resistance exercises were performed for an additional 5 weeks. Flaps showed a similar color match and skin texture compared with the normal skin of the hand. Advantages of the tendocutaneous delayed arterialized venous flap are that a larger flap can be obtained than when using a pure venous flap or arterialized venous flap; the survival rate of the arterialized venous flap increases, which permits the use of a composite flap; the main artery of the donor site is preserved; thin, nonbulky tissue is used; and elevation is easy, without deep dissection. The disadvantages are the two-stage operation, donor-site scarring, and weak extension of the toes.
authors.affiliation: Department of Plastic and Reconstructive Surgery, Kyungpook National University Hospital, Taegu, Korea. bccho@kyungpook.ac.kr
authors.forename: B C
authors.initials: BC
authors.lastname: Cho
authors.forename: J S
authors.initials: JS
authors.lastname: Byun
authors.forename: B S
authors.initials: BS
authors.lastname: Baik
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000328:Adult; D017292:Doxazosin / Q000494:pharmacology; D006230:Hand Injuries / Q000601:surgery*; D006801:Humans; D008297:Male; D005996:Nitroglycerin / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D017695:Soft Tissue Injuries / Q000601:surgery*; D013524:Surgical Flaps / Q000098:blood supply*; D013708:Tendon Injuries / Q000601:surgery*; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D014665:Vasodilator Agents; D005996:Nitroglycerin; D017292:Doxazosin